Drugs / DM1157
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03490162 | Jul 2018 → Sep 2019 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM1157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03490162 ↗ |
| Known as | PL-69 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1254709 ↗ |
| Action | Inhibit | “a small molecule that inhibits the formation of hemozoin” PMID 35184256 ↗ Feb 2022 |
| Modality | Small molecule | “a small molecule that inhibits the formation of hemozoin” PMID 35184256 ↗ Feb 2022 |
| Route | Oral | “DM1157 orally” NCT03490162 ↗ |